Tepotinib Evidence: Trial Results and Peer-Reviewed Publications
Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for Tepotinib comprises 23 peer-reviewed publications across 15 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Carcinoma, Non-Small-Cell Lung, Neoplasms, Carcinoma, Hepatocellular, and Stomach Neoplasms. Most recent publication: Prospective evaluation of genomics-guided off-label treatment., Nature, 2026.
Top peer-reviewed publications
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
- Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.Wu YL, Cheng Y, Zhou J, et al. · Lancet Respir Med · 2020
- Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.Ryoo BY, Cheng AL, Ren Z, et al. · Br J Cancer · 2021
- Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.Paik PK, Felip E, Veillon R, et al. · N Engl J Med · 2020
- Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.Wu YL, Guarneri V, Voon PJ, et al. · Lancet Oncol · 2024
- Prospective evaluation of genomics-guided off-label treatment.Verkerk K, Spiekman AC, Haj Mohammad SF, et al. · Nature · 2026
- Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.Mazieres J, Paik PK, Garassino MC, et al. · JAMA Oncol · 2023
- The role of the molecular tumor board: learnings from the ROME trial.Marchetti P, Curigliano G, Westphalen CB, et al. · NPJ Precis Oncol · 2026
- Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.Marchetti P, Curigliano G, Biffoni M, et al. · Nat Med · 2025
Publications by year
2020–2026: 23 publications.
2020
2
2021
2
2022
6
2023
6
2024
3
2025
2
2026
2
Publications by indication
Carcinoma, Non-Small-Cell Lung (13)
- The role of the molecular tumor board: learnings from the ROME trial.
- Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.
- Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
- Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
- Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates.
Neoplasms (6)
- Prospective evaluation of genomics-guided off-label treatment.
- Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.
- Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
- Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
- Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.
Carcinoma, Hepatocellular (3)
- Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.
- Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.
- Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Stomach Neoplasms (1)
- Adding Docetaxel to Tepotinib to Overcome Oligoprogression in MET Exon 14 Skipping-Mutated NSCLC When Local Therapy Is Unfeasible: A Case Report.
Publications by journal
- Br J Cancer3 papers
- Cancer Chemother Pharmacol3 papers
- Future Oncol2 papers
- Lancet Respir Med1 paper
- N Engl J Med1 paper
- Int J Cancer1 paper
- Invest New Drugs1 paper
- Lancet Oncol1 paper
- Nature1 paper
- Thorac Cancer1 paper
All Tepotinib publications (23)
2026 (2 papers)
- Prospective evaluation of genomics-guided off-label treatment.Verkerk K, Spiekman AC, Haj Mohammad SF, et al. · Nature · 2026 · Derived
- The role of the molecular tumor board: learnings from the ROME trial.Marchetti P, Curigliano G, Westphalen CB, et al. · NPJ Precis Oncol · 2026 · Derived
2025 (2 papers)
- Adding Docetaxel to Tepotinib to Overcome Oligoprogression in MET Exon 14 Skipping-Mutated NSCLC When Local Therapy Is Unfeasible: A Case Report.Sánchez García D, Grau Mirete B, Rodríguez Payá P, et al. · Case Rep Oncol Med · 2025 · Derived
- Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.Marchetti P, Curigliano G, Biffoni M, et al. · Nat Med · 2025 · Derived
2024 (3 papers)
- Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.Wu YL, Guarneri V, Voon PJ, et al. · Lancet Oncol · 2024 · Derived
- Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.Kato T, Yang JC, Ahn MJ, et al. · Br J Cancer · 2024 · Derived
- Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.Geurts BS, Zeverijn LJ, Leek LVM, et al. · Clin Cancer Res · 2024 · Derived
2023 (6 papers)
- Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.Zeverijn LJ, Looze EJ, Thavaneswaran S, et al. · Int J Cancer · 2023 · Derived
- Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates.Yalkinoglu Ö, Becker A, Krebs-Brown A, et al. · Invest New Drugs · 2023 · Derived
- Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.Mazieres J, Paik PK, Garassino MC, et al. · JAMA Oncol · 2023 · Derived
- Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B.Le X, Paz-Ares LG, Van Meerbeeck J, et al. · Cell Rep Med · 2023 · Derived
- Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping.Hallick J, Baird AM, Falchook G, et al. · Future Oncol · 2023 · Derived
- Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.Geurts BS, Battaglia TW, van Berge Henegouwen JM, et al. · BMC Cancer · 2023 · Derived
2022 (6 papers)
- Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study.Xiong W, Papasouliotis O, Jonsson EN, et al. · Cancer Chemother Pharmacol · 2022 · Derived
- Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.Xiong W, Hietala SF, Nyberg J, et al. · Cancer Chemother Pharmacol · 2022 · Derived
- Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.van Berge Henegouwen JM, van der Wijngaart H, Zeverijn LJ, et al. · Cancer Chemother Pharmacol · 2022 · Derived
- MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC.Tyler LC, Le AT, Chen N, et al. · Thorac Cancer · 2022 · Derived
- Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.Nakauma-González JA, Rijnders M, van Riet J, et al. · Eur Urol · 2022 · Derived
- INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance.F Smit E, Dooms C, Raskin J, et al. · Future Oncol · 2022 · Background
2021 (2 papers)
- Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.Ryoo BY, Cheng AL, Ren Z, et al. · Br J Cancer · 2021 · Trial result
- Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.Decaens T, Barone C, Assenat E, et al. · Br J Cancer · 2021 · Derived
2020 (2 papers)
- Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.Wu YL, Cheng Y, Zhou J, et al. · Lancet Respir Med · 2020 · Trial result
- Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.Paik PK, Felip E, Veillon R, et al. · N Engl J Med · 2020 · Trial result
Sources and methodology
- Publications:
ctgov.study_references(PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference typesRESULT,DERIVED, andBACKGROUND. - Per-arm outcome values:
ctgov.outcome_measurementsjoined toctgov.design_outcomeswhereoutcome_type = 'PRIMARY', restricted to phasePHASE3andPHASE2/PHASE3. - Publication metadata (title, journal, year, authors): PubMed E-utilities
efetch.fcgi - Data freshness: Wed, 20 May 2026 23:45:40 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).